

# OTR3

Matrix Therapy for Regeneration

## COMPANY PRESENTATION

### Deliver the full potential of RGTA<sup>®</sup>

---

March 2022

## General Overview

- Founded in 2000, OTR3 is a commercial stage and independent<sup>1</sup> biotech company, focused on expanding its proprietary technology RGTA<sup>®</sup> across indications with high unmet needs .
- The company has been reorganised in 2021 with a new management team in order to deliver the full potential of RGTA<sup>®</sup>.

## Business Strategy

- Expand and diversify our revenue stream.
- Design and develop new generations of RGTA<sup>®</sup>.
- Accelerate the current clinical programs to generate remarkable data.
- Open to partnership or licensing opportunities.

## Operating Model

- OTR3 operates as technology platform aiming partnerships for late stages clinical development.
- R&D operations are split into in-house activities and outsourced activities between qualified CROs and CDMOs as well as scientific collaborations.
- Commercial strategy is based on a growing distributors network.
- The company headcounts is intentionally limited to 11 employees (excluding temps).

## Key Metrics

- More than 200 publications and 50 patents.
- Self-funding thanks to +2m€ revenue from sales per year and French state or EU grants.
- More than 150.000 patients treated with RGTA<sup>®</sup> compounds.
- 3 commercialised products and 3 promising products under clinical development phases.

1. No institutional investors in the shareholder structure for the moment. OTR3 is now opened to discuss with both industrial and institutional investors.



**Denis BARRITAULT**  
Founder and CEO

Emeritus Professor  
and former head CRRET  
laboratories CNRS University  
Paris-Est Creteil.  
Owner of more than 200  
publications and 50 Patents.



**Frederic SEDEL**  
General manager and  
Chief Medical Officer

MD, PhD, Neurologist, Hospital  
Practitioner and Doctor of  
Sciences. Former CEO, CSO  
and Co-Founder at MedDay  
pharmaceuticals.



**Agnes CHOPPIN**  
Chief Scientific Officer

PhD, pharmacologist,  
25 years of preclinical  
experience in pharmaceutical  
industry, CROs  
management and submissions  
to agencies.



**Aly KARAMOKO**  
Chief Financial Officer

Master in accounting, Master  
in strategy and finance from  
EM LYON and a Certification in  
Merger and Acquisition from  
INSEAD, Expert in non-dilutive  
and dilutive funding.



**Laurent PINCHARD**  
Chief Operating Officer

Engineer from the “Ecole  
Centrale Paris” with a  
background in organic  
chemistry and pharmacology.  
Expert in products  
development.

## RGTA<sup>®</sup> Description


- RGTA<sup>®</sup> are ReGeneraTing Agents designed and developed to act as Heparan Sulphate mimetic polymers and able to reconstruct the extracellular matrix scaffold around the cells.

## Breakthrough mechanism of action


- RGTA<sup>®</sup> molecules promote natural tissue regeneration by interacting with the extracellular matrix (ECM) components and protect tissue specific endogenous communication peptides and scaffold proteins.

### Extracellular matrix destruction process caused by lesions


#### 1 ECM before lesion



#### 2 ECM during lesion





#### 3 ECM after lesion



### Tissue repairing and regeneration with RGTA<sup>®</sup>


#### 4 RGTA<sup>®</sup> impact on ECM





**CACIPLIQ<sup>®</sup>**  
RGTA<sup>®</sup>**Clerapliq<sup>®</sup>****Dermapliq<sup>®</sup>**  
Spray

More than 150.000 cumulated patients and a growing network of distributors.



Contact for distribution agreement:  
**[sales@otr3.com](mailto:sales@otr3.com)**



Contact for investors and partnership:  
**[bd@otr3.com](mailto:bd@otr3.com)**

